Genfit S.A. (OTCMKTS:GNFTF – Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,905 shares, an increase of 269.9% from the June 30th total of 515 shares. Based on an average trading volume of 105 shares, the short-interest ratio is presently 18.1 days.
Genfit Price Performance
Genfit stock opened at $15.95 on Monday. Genfit has a 52-week low of $4.14 and a 52-week high of $15.95. The firm has a 50-day moving average price of $10.61 and a two-hundred day moving average price of $9.57.
About Genfit
Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.
In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.
Featured Articles
- Five stocks we like better than Genfit
- These 3 AI Winners Don’t Sell the Tech—They Use It
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
